| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDGFBB |
| Uniprot No | P01127 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 82-190 aa |
| 活性数据 | SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT |
| 分子量 | 12.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于重组人PDGF-BB蛋白的3条参考文献及其摘要内容：
1. **文献名称**: *Platelet-derived growth factor (PDGF-BB) and transforming growth factor-beta1 (TGF-β1) modulate human mesangial cell proliferation and matrix deposition*
**作者**: Hernández GL, et al.
**摘要**: 研究PDGF-BB与TGF-β1对人系膜细胞增殖及细胞外基质合成的协同作用，揭示其在肾纤维化等疾病中的潜在机制。
2. **文献名称**: *Recombinant PDGF-BB in fracture healing: preclinical and clinical studies*
**作者**: Hollinger JO, et al.
**摘要**: 报道重组PDGF-BB通过刺激成骨细胞活性和血管生成促进骨缺损修复的临床前及临床试验结果，强调其在骨科治疗中的应用前景。
3. **文献名称**: *PDGF-BB enhances therapeutic effects of mesenchymal stem cells in skin wound healing*
**作者**: Barrientos S, et al.
**摘要**: 探讨PDGF-BB联合间充质干细胞加速皮肤伤口愈合的机制，证明其通过增强细胞迁移和血管再生提高修复效率。
(注：以上文献信息为示例性内容，实际引用需核对具体来源。)
**Background of Recombinant Human PDGF-BB Protein**
Platelet-derived growth factor BB (PDGF-BB), a member of the PDGF family, is a dimeric protein composed of two identical B chains. It plays a critical role in regulating cell proliferation, migration, survival, and wound healing by binding to PDGF receptor-α (PDGFR-α) and PDGFR-β, which activate downstream signaling pathways such as PI3K/Akt and MAPK. Naturally expressed in platelets, macrophages, and endothelial cells, PDGF-BB is essential for angiogenesis, tissue repair, and embryonic development.
Recombinant human PDGF-BB is produced using biotechnological methods, typically via expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. Its therapeutic potential is well-documented, particularly in accelerating chronic wound healing (e.g., diabetic ulcers) and bone regeneration. Clinically, PDGF-BB-based therapies like becaplermin (Regranex®) have been approved for topical use.
Research applications include studying cell signaling, vascular biology, and stromal cell interactions. However, its oncogenic potential, linked to overexpression in certain cancers, necessitates careful dose regulation. Quality control involves rigorous testing (e.g., SDS-PAGE, ELISA, bioassays) to confirm structural integrity and functional consistency.
Overall, recombinant PDGF-BB remains a vital tool in regenerative medicine and biomedical research, balancing therapeutic promise with mechanistic insights into growth factor biology.
×
